Background: Gaucher disease (GD) encompasses a broad clinical spectrum ranging from non-neuronopathic to severe neuronopathic forms. Although newborn screening (NBS) for GD has been implemented in several regions worldwide, long-term outcome data for patients with neuronopathic GD remain limited. Therefore, we evaluated the clinical characteristics, genotypes, treatments, and long-term outcomes of patients with GD identified through a regional population-based NBS program in Japan.,Methods: We retrospectively analyzed patients diagnosed with GD through a regional population-based NBS program in Japan between 2016 and 2025. Screening was based on the glucocerebrosidase activity in dried blood spots, with confirmatory clinical, biochemical, and genetic evaluations.,Results: Among the 341,029 newborns screened, 17 (0.0050%) were recalled for repeat testing, and seven were diagnosed with GD. Compared with our previous report, one patient was reclassified from GD3 to classic GD2 during the extended follow-up. Consequently, the final cohort included one patient with GD1, three with GD2, two with GD3, and one unclassified. Enzyme replacement therapy (ERT) was initiated in all patients. The patient with GD1 remained clinically stable during follow-up. All patients with GD2 died despite treatment. Patients with GD3 developed slow horizontal saccades but showed improvement in hematological and visceral manifestations under ERT.,Conclusions: A regional population-based NBS approach enabled identifying patients with a broad and evolving phenotypic spectrum of GD. Long-term follow-up is important for accurate disease classification and reclassification. Although current therapies for neuronopathic diseases are inefficient, NBS allows early diagnosis and longitudinal clinical monitoring.